ORHub, Inc. (OTC PINK:ORHB) has acquired 100% equity interest in PUR Biologics, LLC, marking its entry into the global medical device market, projected to reach $445.1 billion by 2026. The acquisition focuses on utilizing PUR's technologies to regenerate cartilage and alleviate pain related to osteoarthritis and degenerative disc disease. With this strategic move, ORHub aims to enhance treatment options and expand its market presence, including updates to corporate branding and potential uplisting.
ORHub, Inc. (OTC Pink:ORHB) has finalized its agreement to acquire PUR Biologics, LLC, enhancing its capabilities in treating osteoarthritis and joint cartilage issues. The integration of PUR’s patented regenerative and anti-inflammatory technologies aims to replace traditional injectables like cortisone. CEO CJ Wiggins emphasized the potential of these technologies to significantly improve patient outcomes linked to joint conditions. ORHub focuses on digitizing the healthcare payment process and aims to leverage advancements in biopharmaceuticals for better healthcare solutions.
ORHub, Inc. (OTC PINK:ORHB) announced a favorable court ruling on April 5, 2022, dismissing a lawsuit by Frederic Buonincontri and AXT Analytics, LLC with prejudice. The ruling, issued on March 30, allows ORHub to move forward without the burden of litigation. CEO CJ Wiggins expressed satisfaction with the decision, emphasizing the company's focus on restoring shareholder value and advancing the FutureORTM software platform. The company aims to enhance sales and pursue relevant acquisitions in the healthcare sector.
ORHub has made strides in improving hospital relationships with biotech firms, focusing on enhancing surgical experiences. The company recently completed its FutureORTM software, which aims to streamline operations in hospital operating rooms. Additionally, ORHub is pursuing an acquisition of PUR Biologics, known for its innovative bone regeneration and pain management products. Plans for rebranding and strengthening public market communications are underway, with a vision to develop a Digital Health and Regenerative Therapeutic division. ORHub's leadership expresses optimism about future growth and shareholder value.
ORHub (OTC PINK:ORHB) announced plans for a complete acquisition of PUR Biologics, enhancing its biologic implant and regenerative technology division. This strategic move aims to complement ORHub's digital health initiatives and leverage PUR's patent portfolio in cell therapy, thus expanding its market presence in healthcare. CEO CJ Wiggins highlighted the significance of integrating digital business with biotech solutions for sustainable healthcare improvements.
ORHub, Inc. (OTC PINK: ORHB) has announced the appointment of Sean McMenamin to its Board of Directors, enhancing the board's oversight with his financial expertise. CEO CJ Wiggins expressed gratitude, noting McMenamin's potential to contribute significantly to the company's leadership and strategic acquisitions. McMenamin emphasized the opportunity for ORHub to transform financial transactions in healthcare, benefiting hospitals and medical device manufacturers. ORHub aims to innovate healthcare management through intelligent automation and connected mobility solutions.
ORHub, Inc. (OTC PINK:ORHB) has reported a significant six-figure revenue event alongside increasing customer requests for its FutureOR technology, demonstrating successful progress towards its goal of transforming surgical business processes. The company aims to launch FutureOR and V-Pay applications in Q2 2022, focusing on enhancing productivity and cash-flow management. ORHub is committed to developing innovative healthcare technologies that improve both patient outcomes and the business dynamics between hospitals and medical vendors.
ORHub is set to launch a new Surgical Resource Management operating system aimed at improving implant accountability and operational efficiency in the medical device industry by Q2 2022. This system focuses on Intelligent Automation to enhance communication and transaction processes between hospitals and vendors. CEO CJ Wiggins emphasized the need for reform in the current surgical implant information management to reduce costs and inefficiencies. The company's solutions aim to leverage IoT for better data handling and vendor relationships in healthcare.
ORHub (OTC PINK:ORHB) announced significant progress in 2021, amidst preparations for an ambitious 2022. The company reduced debt by over $7.5M, developed a new digital payment platform for biomedical devices, and settled long-standing litigation by surrendering note agreements. ORHub is positioned to launch new products and engage in acquisition discussions, underscoring its commitment to the market and stakeholders. CEO CJ Wiggins expressed confidence in ORHub's potential to revolutionize healthcare through innovative solutions, backed by strategic partnerships.